- Price
- $221.97
- Day
- -0.73%
- Mkt Cap
- $32.20B
- 52W Range
- $180.27 – $284.87
- Volume
- 979.4K
- Beta
- 0.77
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
ResMed NYSE: RMD outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care.
Read full article
Engineers Gate Manager LP raised its stake in ResMed Inc. (NYSE: RMD) by 77.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,127 shares of the medical equipment provider's stock after acquiring an additional 3,555 shares during the period. Engineers Gate
Read full article
Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold moves on names like Eli Lilly, Etsy, Northrop Grumman, and Rivian. Find out which stocks got upgraded, downgraded, or newly covered before the opening bell.
Read full article
ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read full article
AI regulation odds have sharply declined after Trump dismissed AI takeover concerns during a public call with Nvidia (NVDA) CEO Jensen Huang. ResMed (RMD) was upgraded to Outperform by RBC Capital Markets, with a price target raised to $262, citing strong Q4 results and expected high-single-digit EPS growth.
Read full article
Setbacks for competitors have positioned ResMed to capture more market share.
Read full article
RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.
Read full article
ResMed has de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rather than fundamentals. Recurring mask and consumables revenue, now 42% of the sleep and breathing segment, is underappreciated and grew 13% last year. Two major risks—sleep apnea pill and reimbursement—are less material for RMD than feared; Philips' US return poses the most credible threat.
Read full article
A Qualified Charitable Distribution can wipe your RMD off your tax return entirely, but it also kills the income you were counting on. Three ETFs can rebuild that cash flow, and they each do it a completely different way.
Read full article
Hsbc Holdings PLC grew its position in shares of ResMed Inc. (NYSE: RMD) by 13.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 355,518 shares of the medical equipment provider's stock after buying an additional 42,007 shares during
Read full article
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).
Read full article
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. (“ResMed” or the “Company”) (NYSE: RMD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read full article